AIRNA is dedicated to revolutionizing patient care through its innovative RNA editing therapeutics, specifically utilizing its proprietary platform known as RESTORE™. This advanced technology is designed to create genetic medicines that target both rare and common diseases. RESTORE™ builds upon the foundational ADAR platform developed by AIRNA's founders, enhancing its therapeutic capabilities and expanding its ability to address novel genetic targets. The platform operates by precisely editing RNA strands, which is crucial for modifying the genetic code responsible for protein synthesis, thereby enabling the development of effective treatments.

The RESTORE™ platform employs a systematic approach to optimize the chemistry, sequence, and delivery of oligonucleotides (oligos) into cells. Once inside, these oligos engage with specific RNA targets, facilitating site-directed editing through the recruitment of endogenous ADAR enzymes. This process allows for precise adenosine-to-inosine (A-to-I) modifications at targeted sites, effectively altering the RNA code. Such changes can repair pathogenic mutations or induce beneficial mutations that modify protein function, ultimately aiming to restore health and improve patient outcomes. Through these advanced RNA editing techniques, AIRNA is committed to transforming lives by addressing the underlying genetic causes of diseases.

United States

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.

AIRNA

Company Details